Praxis Precision Medicines (PRAX) News Today → America could fall from this event (From Porter & Company) (Ad) Free PRAX Stock Alerts $45.90 +0.71 (+1.57%) (As of 05/14/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 14 at 8:10 AM | marketbeat.comPraxis Precision Medicines (NASDAQ:PRAX) Rating Reiterated by HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $105.00 price objective on shares of Praxis Precision Medicines in a research report on Tuesday.May 14 at 7:23 AM | finance.yahoo.comWe're Hopeful That Praxis Precision Medicines (NASDAQ:PRAX) Will Use Its Cash WiselyMay 13 at 5:11 PM | marketbeat.comPraxis Precision Medicines (NASDAQ:PRAX) Shares Gap Down to $48.78Praxis Precision Medicines (NASDAQ:PRAX) Shares Gap Down to $48.78May 13 at 4:21 PM | marketwatch.comPraxis Precision Medicines Shares Drop 5% After 1Q Results Miss ExpectationsMay 13 at 11:21 AM | finanznachrichten.dePraxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial ResultsMay 13 at 11:21 AM | msn.comPraxis Precision Medicines GAAP EPS of -$2.84 misses by $0.75, revenue of $0.43M misses by $1.33MMay 13 at 7:00 AM | globenewswire.comPraxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial ResultsMay 13 at 1:34 AM | americanbankingnews.comComparing LifeVantage (NASDAQ:LFVN) & Praxis Precision Medicines (NASDAQ:PRAX)May 12 at 3:19 PM | markets.businessinsider.comPraxis Precision Medicines is about to announce earnings — here's what Wall Street expectsMay 12 at 3:21 AM | americanbankingnews.comPraxis Precision Medicines (PRAX) Set to Announce Quarterly Earnings on MondayMay 11 at 8:37 AM | marketbeat.comPraxis Precision Medicines (PRAX) Scheduled to Post Earnings on MondayPraxis Precision Medicines (NASDAQ:PRAX) will be releasing earnings before the market opens on Monday, May 13, Zacks reports.May 10, 2024 | globenewswire.comPraxis Precision Medicines to Report First Quarter 2024 Financial Results on Monday, May 13, 2024May 4, 2024 | americanbankingnews.comXOMA (NASDAQ:XOMA) & Praxis Precision Medicines (NASDAQ:PRAX) Head-To-Head ContrastMay 3, 2024 | globenewswire.comPraxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 1, 2024 | msn.comBaird Initiates Coverage of Praxis Precision Medicines (PRAX) with Outperform RecommendationMay 1, 2024 | marketbeat.comPraxis Precision Medicines (NASDAQ:PRAX) Now Covered by Analysts at Robert W. BairdRobert W. Baird began coverage on shares of Praxis Precision Medicines in a report on Wednesday. They set an "outperform" rating and a $117.00 price target for the company.April 30, 2024 | msn.comGoldman Sachs revamps "high-quality" stock picks listApril 30, 2024 | msn.comBankrupt national retailer pins hopes on popular new serviceApril 26, 2024 | tmcnet.comMedaptus and Banner Health Partner to Revolutionize Charge Processing with Charge Pro: Beyond Automation to Enhanced Efficiency and PrecisionApril 26, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Hookipa Pharma (HOOK), Praxis Precision Medicines (PRAX) and Blueprint Medicines (BPMC)April 26, 2024 | marketbeat.comHC Wainwright Reiterates Buy Rating for Praxis Precision Medicines (NASDAQ:PRAX)HC Wainwright reiterated a "buy" rating and issued a $105.00 price objective on shares of Praxis Precision Medicines in a report on Friday.April 22, 2024 | marketbeat.comPraxis Precision Medicines (NASDAQ:PRAX) Sees Strong Trading VolumePraxis Precision Medicines (NASDAQ:PRAX) Sees Unusually-High Trading VolumeApril 22, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: BioCryst (BCRX), Ironwood Pharma (IRWD)April 17, 2024 | msn.comWhy an ALS Drug Was Pulled From the MarketApril 17, 2024 | marketbeat.comPraxis Precision Medicines (NASDAQ:PRAX) Stock Price Down 2.6%Praxis Precision Medicines (NASDAQ:PRAX) Shares Down 2.6%April 12, 2024 | globenewswire.comPraxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual MeetingApril 11, 2024 | marketbeat.comBrokers Offer Predictions for Praxis Precision Medicines, Inc.'s Q2 2024 Earnings (NASDAQ:PRAX)Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) - Research analysts at Wedbush lifted their Q2 2024 earnings per share (EPS) estimates for Praxis Precision Medicines in a report released on Monday, April 8th. Wedbush analyst L. Chico now expects that the company will post earnings ofApril 9, 2024 | marketbeat.comPraxis Precision Medicines (NASDAQ:PRAX) Shares Down 2.5% Praxis Precision Medicines (NASDAQ:PRAX) Stock Price Down 2.5%April 8, 2024 | marketbeat.comPraxis Precision Medicines (NASDAQ:PRAX) Shares Up 5.1%Praxis Precision Medicines (NASDAQ:PRAX) Trading 5.1% HigherApril 5, 2024 | globenewswire.comPraxis Precision Medicines to Participate in Upcoming April ConferencesApril 3, 2024 | marketbeat.comPraxis Precision Medicines (NASDAQ:PRAX) Stock Price Down 6.1%Praxis Precision Medicines (NASDAQ:PRAX) Stock Price Down 6.1%April 2, 2024 | globenewswire.comPraxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 31, 2024 | marketbeat.comCitigroup Inc. Grows Holdings in Praxis Precision Medicines, Inc. (NASDAQ:PRAX)Citigroup Inc. increased its position in shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) by 44,585.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 83,115 shares of the company's stock after buyinMarch 28, 2024 | markets.businessinsider.comPraxis Precision Medicines Announces Pricing Of Underwritten Public OfferingMarch 28, 2024 | globenewswire.comPraxis Precision Medicines, Inc. Announces Pricing of $200 Million Public OfferingMarch 27, 2024 | globenewswire.comPraxis Precision Medicines, Inc. Announces Proposed Public OfferingMarch 27, 2024 | marketbeat.comPraxis Precision Medicines (NASDAQ:PRAX) Shares Down 3.8% Praxis Precision Medicines (NASDAQ:PRAX) Stock Price Down 3.8%March 26, 2024 | msn.comPraxis gains after mid-stage data for epilepsy candidateMarch 26, 2024 | markets.businessinsider.comPraxis Precision Medicines Reports Positive Results From PRAX-628 Study - Quick FactsMarch 26, 2024 | markets.businessinsider.comBuy Rating Affirmed for Praxis Precision Medicines’ PRAX-628 Based on Strong Clinical Trial Outcomes and Market PotentialMarch 26, 2024 | msn.comWhy Praxis Precision Medicines Stock Is Trading Higher TuesdayMarch 26, 2024 | finance.yahoo.comTop 1% Biotech, Praxis, Releases 'Fireworks' And Catapults To Year-HighMarch 26, 2024 | marketbeat.comJefferies Financial Group Increases Praxis Precision Medicines (NASDAQ:PRAX) Price Target to $128.00Jefferies Financial Group boosted their price objective on shares of Praxis Precision Medicines from $75.00 to $128.00 and gave the company a "buy" rating in a report on Tuesday.March 26, 2024 | seekingalpha.comPraxis: 2nd Half 2024 ET Readout Could Lead To U.S. Regulatory FilingMarch 26, 2024 | marketbeat.comPraxis Precision Medicines (NASDAQ:PRAX) Sets New 52-Week High at $66.57Praxis Precision Medicines (NASDAQ:PRAX) Reaches New 1-Year High at $66.57March 26, 2024 | globenewswire.comPraxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated PatientsMarch 25, 2024 | globenewswire.comPraxis Precision Medicines to Host PRAX-628 Program UpdateMarch 25, 2024 | finance.yahoo.comA Look At The Intrinsic Value Of Praxis Precision Medicines, Inc. (NASDAQ:PRAX)March 21, 2024 | marketbeat.comPraxis Precision Medicines (NASDAQ:PRAX) Stock Price Down 4.5%Praxis Precision Medicines (NASDAQ:PRAX) Trading Down 4.5%March 20, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), Clene (CLNN) and Jazz Pharmaceuticals (JAZZ) Get Praxis Precision Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for PRAX and its competitors with MarketBeat's FREE daily newsletter. Email Address The World’s Richest Man Blindsided by AI (Ad)These billionaires know that early investors in AI stand to make a lot of money. The same is true for everyday Americans... including you. Get the full story here. PRAX Media Mentions By Week PRAX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PRAX News Sentiment▼-0.010.56▲Average Medical News Sentiment PRAX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PRAX Articles This Week▼152▲PRAX Articles Average Week Get Praxis Precision Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for PRAX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: 89bio News Today OPKO Health News Today Arcutis Biotherapeutics News Today ALX Oncology News Today ARS Pharmaceuticals News Today ABIVAX Société Anonyme News Today Ocular Therapeutix News Today Immunome News Today Zentalis Pharmaceuticals News Today Tyra Biosciences News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PRAX) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersDid Intel Just Dethrone Nvidia?Chaikin AnalyticsRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressCharles Payne Demystifies OptionsUnstoppable ProsperityElon to Transform U.S. Economy? Porter & CompanyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Praxis Precision Medicines, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.